AU723604B2 - Cytopathic viruses for therapy and prophylaxis of neoplasia - Google Patents

Abstract

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.

Description

WO 98/29555 PCT/US97/22036 CYTOPATHIC VIRUSES FOR THERAPY AND PROPHYLAXIS OF NEOPLASIA TECHNICAL FIELD The invention provides compositions of recombinant cytopathic viruses which are capable of replication and/or expression of late region genes in neoplastic mammalian cells but are essentially non-replicable in non-neoplastic cells, methods for constructing and propagating such recombinant viruses, methods for treating neoplastic disease with such recombinant viruses, and therapeutic compositions comprising such recombinant viruses.

BACKGROUND

The proliferation of normal cells is thought to be regulated by growth-promoting proto-oncogenes counterbalanced by growth-constraining tumor-suppressor genes. Mutations that potentiate the activities of proto-oncogenes create the oncogenes that force the growth of neoplastic cells. Conversely, genetic lesions that inactivate tumor suppressor genes, generally through mutation(s) that lead to a cell being homozygous for the inactivated tumor suppressor allele, can liberate the cell from the normal replicative constraints imposed by these genes.

Usually, an inactivated tumor suppressor gene p53, RB, DCC, NF-I) in combination with the formation of an activated oncogene a proto-oncogene containing an activating structural or regulatory mutation) can yield a neoplastic cell capable of essentially unconstrained growth a transformed cell).

Oncogenic transformation of cells leads to a number of changes in cellular metabolism, physiology, and morphology. One characteristic alteration of oncogenically transformed cells is a loss of responsiveness to constraints on cell proliferation and differentiation normally imposed by the appropriate expression of cell- growth regulatory genes.

While different types of genetic alterations may all lead to altered expression or function of cell-growth regulatory genes and to abnormal growth, it is generally believed that more than one event is required to lead to neoplastic transformation of a normal cell to a 1 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 malignant one (Land et al. (1983) Nature 304: 596; Weinberg RA (1989) Cancer Res. 49: 3713). The precise molecular pathways and secondary changes leading to malignant transformation for most cell types are not clear. A number of cases have been reported in which altered expression or activity of some proteins with putative cell-cycle control functions and/or implicated in the formation of functional transcriptional complexes, such asp53 and RB, can lead to loss of proliferation control in cells (Ullrich et al. (1992)J. Biol. Chem. 267: 15259; Hollstein et al. (1991) Science 253: 49; Sager R (1992) Curr. Opin. Cell. Biol. 4: 155; Levine et al. (1991) Nature 351: 453).

Some oncogenes have been found to possess characteristic activating mutations in a significant fraction of certain cancers. For example, particular mutations in the ras" and ras K coding regions codon 12, codon 61; Parada et al. (1984) Nature 312: 649) and the APC gene (Powell et al. (1992) Nature 359: 235) are associated with oncogenic transformation of cultured cells and are present in a striking percentage of specific human cancers colon adenocarcinoma, bladder carcinoma, lung carcinoma and adenocarcinoma, hepatocarcinoma).

These findings have led to the development of diagnostic and therapeutic reagents polynucleotide probes and antibodies) that specifically recognize the activated form(s) of such oncogenes Patent 4,798,787 and U.S. Patent 4,762,706).

The excessive or inappropriate expression of other oncogenes, such as myc, erbB-2, and pim-1, appears to be able to potentiate oncogenic transformation without necessarily requiring the presence of activating mutation(s) in the coding region.

Overexpression of erbB-2 is frequently found in adenocarcinoma of the breast, stomach, and ovary, and erbB-2 levels in these cell types might serve as a diagnostic marker for neoplasia and/or may correlate with a specific tumor phenotype resistance to specific drugs, growth rate, differentiation state).

Transgenic animals harboring various oncogenes Patent 4,736,866 and U.S. Patent 5,087,571) or functionally disrupted tumor suppressor genes (Donehower et al.

(1992) Nature 356: 215) have been described for use in carcinogen screening assays, among other potential uses.

Despite this progress in developing a more defined model of the molecular mechanisms underlying the transformed phenotype and neoplasia, few significant therapeutic methods applicable to treating cancer beyond conventional chemotherapy have resulted. Many conventional chemotherapeutic agents have a low therapeutic index, with therapeutic dosage levels being at or near dosage levels which produce toxicity. Toxic side effects of most 2 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 conventional chemotherapeutic agents arc unpleasant and lead to life-threatening bone marrow suppression, among other side effects.

Recent approaches for performing genc therapy to correct or supplement defective alleles which cause congenital diseases, such as cystic fibrosis, have been attempted with reports of limited initial success. Some gene therapy approaches involve transducing a polynucleotide sequence capable of expressing a functional copy of a defective allele into a cell in vivo using replication-deficient recombinant adenovirus (Rosenfeld et al. (1992) Cell 68: 143). Some of these gene therapy methods are efficient at transducing polynucleotides into isolated cells explanted from a patient, but have not been shown to be highly efficient in vivo.

Therapeutic approaches to cancer which rely on transfection of explanted tumor cells with polynucleotides encoding tumor necrosis factor (TNF) and interleukin-2 (IL-2) have been described (Pardoll D (1992) Curr. Opin. Oncol.4: 1124).

Although it might someday prove possible for gene therapy methods to be <*9O adapted to correct defective alleles of oncogenes or tumor suppressor genes in transformed cells in vivo, present gene therapy methods have not been reported to be able to efficiently transduce and correctly target by homologous recombination) a sufficient percentage of 2: neoplastic cells for practical gene therapy of neoplasia in situ. The nature of cancer biology mandates that a substantial fraction of the neoplastic cells, preferably all of theclonal progeny of the transformed cell, are ablated for an effective therapeutic effect. Moreover, present methods for gene therapy are very expensive, requiring ex vivo culturing of explanted cells 9. Sprior to reintroduction into a patient. Widespread application of such methods, even if they were effective, would be prohibitively expensive.

Thus there exists a need in the art for methods and compositions for diagnosis and therapy of neoplastic diseases, especially for methods which selectively ablate neoplastic cells without the undesirable killing of non-neoplastic cells that is typical of conventional antineoplastic chemotherapy. The present invention fulfills these and other needs.

The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

The above discussion of documents, act, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters rmed part of the prior art base or were common general knowledge in the field re ant to the present invention as it existed in Australia before the priority date of each cli of this application.

SUMMARY OF THE INVENTION The present invention provides a method for ablating neoplastic cells in a cell population, comprising the steps of: Contacting under .infective conditions a recombinant replication deficient adenovirus lacking an expressed viral oncoprotein capable of binding a functional tumor suppressor gene product said adenovirus having the properties of an adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021, with a cell population comprising non-neoplastic cells containing said functional tumor suppressor gene product capable of forming a bound complex with a viral oncoprotein and neoplastic cells lacking said functional tumor suppressor gene product, thereby generating an infected cell population.

The present invention provides several novel methods and compositions for ablating neoplastic cells by infecting the neoplastic cells with a recombinant adenovirus which is substantially replication deficient in non-neoplastic cells and which exhibits at *i least a partial WO 98/29555 PCT/US97/22036 replication phenotype in neoplastic cells. The difference in replication phenotype of the adenovirus constructs of the invention in neoplastic and non-neoplastic cells provides a biological basis for viral-based therapy of cancer. Expression of adenoviralcytopathic effects, and optionally expression of a negative-selectable drug gene HSVtk), are correlated with the adenoviral replication phenotype characteristic of neoplastic cells infected with the recombinant adenovirus constructs of the invention, thus discriminating between neoplastic and non-neoplastic cells and providing selective cytotoxicity of neoplastic cells. Although the methods are described in detail specifically for adenoviral constructs, the methods are believed to be applicable to essentially any virus type wherein efficient replication requires binding and/or sequestration and/or inactivation of a host cell protein that is present in non-neoplastic cells but is substantially absent or nonfunctional in neoplastic cells p53, RB).

In order for adenovirus to replicate efficiently in cells, the adenoviral Elb gene product, p55, forms a complex with the host cell p 5 3 protein, thereby sequestering and/or inactivating p5 3 and producing a cell that is deficient in p53 function. Such a cell made deficient in p53 function can support replication of the adenovirus. In this way, wild-type adenovirus is able to replicate in cells containing p53, as the adenovirus p55 proteins inactivates and/or sequesters the host cell p53 protein. In one embodiment of the invention, a recombinant adenovirus comprising an Elb locus encoding a mutant p55 protein that is substantially incapable of forming a functional complex with p53 protein in infected cells is administered to an individual or cell population comprising a neoplastic cell capable of being infected by the recombinant adenovirus. The substantial incapacity of the recombinant adenovirus to effectively sequester p53 protein in infected non-neoplastic cells results in the introduced recombinant adenoviral polynucleotide(s) failing to express a replication phenotype in non-neoplastic cells. By contrast, neoplastic cells which lack a functional p5 3 protein support expression of a replication phenotype by the introduced recombinant adenovirus which leads to ablation of the neoplastic cell by an adenoviral cytopathic effect and/or expression of a negative selection gene linked to the replication phenotype. In preferred variations of these embodiments, the recombinant adenovirus comprises an Elb locus encoding a mutant which is substantially incapable of binding p53 and may optionally also lack a functional p19 protein incapable of inhibiting expression of adenoviral early region genes in the presence of Ela polypeptides). Recombinant adenoviruses of the invention may further comprise a mutant p19 gene which produces enhanced cytopathic effects; such a mutant known in the art 4 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 is the p19 cyt mutant gene. However, it may be preferable to retain functional p19 in some mutants to maintain the integrity of viral DNA during the infection.

In an alternative embodiment of the invention, a recombinant adenovirus comprising an Ela locus encoding an Ela protein p289R or p243R) that is substantially incapable of forming a complex with RB protein in infected cells is administered to an individual or cell population comprising a neoplastic cell capable of being infected by the recombinant adenovirus. The substantial incapacity of the recombinant adenovirus to effectively sequester RB protein in infected non-neoplastic cells results in the introduced recombinant adenoviral polynucleotide(s) failing to express a replication phenotype in nonneoplastic cells. By contrast, neoplastic cells which lack a functional RB protein support expression of a replication phenotype by the introduced recombinant adenovirus which leads to ablation of the neoplastic cell by an adenoviral cytopathic effect and/or expression of a negative selection gene linked to the replication phenotype. In preferred variations of these embodiments, the recombinant adenovirus comprises an Ela locus encoding a mutant Ela protein p289R) that lacks a CR1 and/or CR2 domain capable of binding RB (and/or the 300kD polypeptide and/or the 107kD polypeptide) but comprises a functional CR3 domain capable of transactivation of adenoviral early genes. Additional variations of these embodiments include those where the recombinant adenovirus comprises a nonfunctional Ela locus which is substantially incapable of expressing a protein that binds to and inactivatesRB and may optionally also comprise a functional p19 protein capable of stimulating expression of adenoviral early region genes in the absence of Ela function). Recombinant adenoviruses of the invention may further comprise a mutant p19 gene which produces enhanced cytopathic effects; such a mutant known in the art is the p19 cyt mutant gene.

The invention provides novel recombinant adenovirus constructs which are replication defective in non-neoplastic cells but capable of expressing a replication phenotype in neoplastic cells lacking functional p53 and/or RB. The novel recombinant adenovirus constructs comprise a mutation, such as a deletion or point mutation, in the Ela and/or Elb gene regions, especially in the sequences encoding the Elb p55 protein and the CR1 and CR2 domains of the Ela p289R or p243R proteins. In some embodiments, a negative selectable gene, such as an HSV tk gene, is operably linked to an early region E2, Ela, Elb) enhancer/promoter, a late region gene enhancer/promoter major late promoter), or an early or late region promoter with a CMV enhancer, in a recombinant adenovirus construct also comprising an Ela or Elb mutation, so that the negative selectable gene is preferentially SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 transcribed in infected cells which express a replication phenotype neoplastic cells) and provides negative selection of such cells by administration of an effective dosage of a negative selection agent gancyclovir, FIAU). A negative selectable gene may be inserted in place of an Ela and/or Elb structural sequence to concomitantly form an Ela'" replication deficient mutant, Elb replication deficient mutant, or Ela/Elb double mutant, respectively.

Antineoplastic compositions comprising such recombinant adenovirus in a pharmaceutically acceptable form for delivery to a neoplastic cell population in vivo are also provided.

The invention also provides recombinant papovaviruses, such as human papillomavirus (HPV), polyomaviruses BK, JC) and SV40, which lack functional proteins for binding and/or inactivating p5 3 and/or RB. Human papillomavirus mutants lacking expression of functional E6 protein will substantially lack the capacity to effectively degrade p53 and thus will be capable of manifesting a replication phenotype in p53'' cells but not in cells containing a sufficient level of functional p53. Human papillomavirus mutants lacking expression of functional E7 protein will substantially lack the capacity to effectively bind RB and thus will be capable of manifesting a replication phenotype in RB' cells but not in cells containing a sufficient level of functional RB. Human papillomavirus mutants lacking expression of both functional E6 protein and functional E7 protein will substantially lack the capacity to effectively bind RB and p53 thus will be capable of manifesting a replication phenotype in p53"'RB' cells but not in cells containing a sufficient level of functional RB and/or p53.

The invention also provides novel methods for treating a neoplastic disease comprising the steps of administering to a patient a recombinant virus capable of preferentially expressing a replication phenotype and/or expressing a cytopathic effect in a neoplastic cell population as compared to expression in a non-neoplastic cell population.

BRIEF DESCRIPTION OF THE DRAWING FIGURE 1 shows a schematic representation of the domain structure and protein-protein interactions of an adenovirus Ela-289R polypeptide.

FIGURE 2 shows in schematic form the construction of the plasmids p019, p020, and p021.

Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this 6 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.

The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, apolypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturallyoccurring. As used herein, the term "recombinant" indicates that a polynucleotide construct and adenovirus genome) has been generated, in part, by intentional modification by man.

As used herein, the term "replication deficient virus" refers to a virus that preferentially inhibits cell proliferation or induces apoptosis in a predetermined cell population cells substantially lacking p53 and/or RB function) which supports expression of a virus replication phenotype, and which is substantially unable to inhibit cell proliferation, induce apoptosis, or express a replication phenotype in cells comprising normal p53 and RB function levels characteristic of non-replicating, non-transformed cells. Typically, a replication deficient virus exhibits a substantial decrease in plaquing efficiency on cells comprising normal RB and/or p53 function.

As used herein, the term "p5 3 function" refers to the property of having an essentially normal level of a polypeptide encoded by the p53 gene relative to nonneoplastic cells of the same histological type), wherein the p53 polypeptide is capable of binding an Elb p55 protein of wild-type adenovirus 2 or 5. For example, p 5 3 function may be lost by production of an inactive mutant) form of p53 or by a substantial decrease or total loss of expression of p53 polypeptide(s). Also, p53 function may be substantially absent in neoplastic cells which comprise p53 alleles encoding wild-type p53 protein; for example, a genetic alteration outside of the p53 locus, such as a mutation that results in aberrant subcellular processing or localization of p53 a mutation resulting in localization of p53 predominantly in the cytoplasm rather than the nucleus) can result in a loss of p53 function.

As used herein, the term "RB function" refers to the property of having an essentially normal level of a polypeptide encoded by the RB gene relative to nonneoplastic cells of the same histological type), wherein the RB polypeptide is capable of binding an Ela protein of wild-type adenovirus 2 or 5. For example, RB function may be lost by production of an inactive mutant) form of RB or by a substantial decrease or total loss 7 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 of expression of RB polypeptide(s). Also, RB function may be substantially absent in neoplastic cells that comprise RB alleles encoding a wild-type RB protein; for example, a genetic alteration outside of the RB locus, such as a mutation that results in aberrant subcellular processing or localization of RB, may result in a loss of RB function.

As used herein, the term "replication phenotype" refers to one or more of the following phenotypic characteristics of cells infected with a virus such as a replication deficient adenovirus: substantial expression of late gene products, such as capsid proteins adenoviral penton base polypeptide) or RNA transcripts initiated from viral late gene promoter(s), replication of viral genomes or formation of replicative intermediates, (3) assembly of viral capsids or packaged virion particles, appearance of cytopathic effect (CPE) in the infected cell, completion of a viral lytic cycle, and other phenotypic alterations which are typically contingent upon abrogation of p5 3 or RB function in nonneoplastic cells infected with a wild-type replication competent DNA virus encoding functional oncoprotein(s). A replication phenotype comprises at least one of the listed phenotypic characteristics, preferably more than one of the phenotypic characteristics.

The term "antineoplastic replication deficient virus" is used herein to refer to a recombinant virus which has the functional property of inhibiting development or progression of a neoplasm in a human, by preferential cell killing of infected neoplastic cells relative to infected non-replicating, non-neoplastic cells of the same histological cell type.

As used herein, "neoplastic cells" and "neoplasia" refer to cells which exhibit relatively autonomous growth, so that they exhibit an aberrant growth phenotype characterized by a significant loss of control of cell proliferation. Neoplastic cells comprise cells which may be actively replicating or in a temporary non-replicative resting state or Go); similarly, neoplastic cells may comprise cells which have a well-differentiated phenotype, a poorlydifferentiated phenotype, or a mixture of both type of cells. Thus, not all neoplastic cells are necessarily replicating cells at a given timepoint. The set defined as neoplastic cells consists of cells in benign neoplasms and cells in malignant (or frank) neoplasms. Frankly neoplastic cells are frequently referred to as cancer, typically termed carcinoma if originating from cells of endodermal or ectodermal histological origin, or sarcoma if originating from cell types derived from mesoderm.

As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or 8 SUBSTITUTE SHEET rule 26 enhancer is operably linked to a coding sequence if it affects tile transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. However, since enhancers generally function when separated from the promoter by several kilobases and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not contiguous.

As used herein, "physiological conditions" refers to an aqueous environment having an ionic strength, pH, and temperature substantially similar to conditions in an intact mammalian cell or in a tissue space or organ of a living mammal. Typically, physiological conditions comprise an aqueous solution having about 150 mM NaCl (or optionally KCI), pH 6.5-8.1, and a temperature of approximately 20-45" C. Generally, physiological conditions are suitable binding conditions for intermolecular association of biological macromolecules. For 'xample, physiological conditions of 150 mM NaCI, pH 7.4, at 37 0 C are generally suitable.

Throughout the description and claims of this specification, the word "comprise" variations of the word, such as "comprising" and "comprises", is not intended to *exclude other additives of components or integers or steps.

S DETAILED DESCRIPTION Generally, the nomenclature used hereafter and the laboratory procedures in cell 0*:culture, molecular genetics, and molecular virology described below are those well known and :commonly employed in the art. Standard techniques are used for recombinant nucleic acid methods, polynucleotide synthesis, polypeptide synthesis, generation and propagation of virus stocks (including cell lines capable of trans-complementation of replication deficient virus stocks), cell culture, and the like. Generally enzymatic reactions and purification steps are performed according to the manufacturer's specifications. The techniques and procedures are generally performed according to conventional methods in the art and various general references (see, generally, Sambrook et al. Molecular Cloning: A Laboratory Manual, 2d ed.

(1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, Virology, Second edition, eds. Fields BN and Knipe DM, (1990) Raven Press, New York, NY, incorporated herein by reference) which are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Neoplasia is a pathological condition which is characterized, in part, by the generation of ncoplastic cells having variant genotypes and phenotypes. Somc tumors may comprise a population of cells lacking RI? function but having p5 3 function; such cells arc designated RB'. Some tumor cells may lack p 53 function but have RB function; such cells are designated p53''. Some tumors may comprise cells lacking both p53 and RB and are q 0**e 0e 555*

S

*S

S

S

S

55.5

S

S..

S*

SS

WO 98/29555 PCT/US97/22036 designated p53''RB"'. The cell line SAOS2 (infra, see Experimental Example) is an example of a neoplastic cell type which is Also, there may be neoplastic cells which comprise essentially normal levels of p53 and RB; such cells having both normal p53 and normal RB may lack other oncoproteins tumor suppressor gene products other thanp53 or RB) which can provide the basis for antineoplastic viral constructs which can preferentially manifest a replication phenotype in such neoplastic cells.

A basis of the present invention is that several DNA viruses which infect mammalian cells adenoviruses; papovaviruses such as BK and JC, SV40, and papillomaviruses such as HPV, and the like) encode viral proteins which are essential for efficient progression through the viral replication cycle; some of these viral proteins sequester cellular proteins, such as those involved in cell-cycle control and/or formation of transcription complexes, as a necessary condition for efficient viral replication. In the absence of the viral proteins which bind, sequester, or degrade such cellular proteins as p53 and RB, viral replication is substantially inhibited. Normal non-neoplastic) cells which are infected with a mutant virus lacking the ability to sequester or degrade p53 and/or RB are generally unable to support replication of the mutant virus, hence such mutant viruses are considered to be replication deficient (or replication defective). However, since the sequestration or degradation of p53 or RB is not necessary for viral replication in cells which lack functional p53 or RB (such cells are designated p53" and RB'" respectively) it is possible that replication deficient mutant viruses which are defective for p53 and/or RB sequestration or degradation may express a replication phenotype in such p 5 3 or RB'' cells to a greater extent than in cells having essentially normal p53 and/or RB function. Neoplastic cells frequently lack p5 3 function (a p53'" cell), RB function (a RB cell), or both functions (a p53"RB" cell). Hence, some replication deficient viral mutants may preferentially exhibit a replication phenotype in neoplastic cells.

Viral mutants lacking the capacity to express a functional RB inactivating protein adenovirus Ela, HPV E7 protein) will manifest a replication phenotype in RB" cells and RB"p53" cells. Viral mutants lacking the capacity to express a functional p53 inactivating protein adenovirus Elb p55, HPV E6 protein) will manifest a replication phenotype in p53' cells and RB'"p53 cells. Viral mutants lacking the capacity to express both a functional p53 inactivating protein adenovirus Elb p55, HPV E6 protein) and a functional RB inactivating protein adenovirus Ela, HPV E7 protein) will manifest a replication phenotype in RB"p53" cells. Cytotoxicity linked to the expression of a replicative SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 phenotype can therefore be used as a basis for preferentially killing neoplastic cells having a RB p53'', or RB'"p53 phenotype. Although some replicating non-neoplastic cells may transiently exhibit a RB'' phenotype, p53"' phenotype, or RB~'p53'" phenotype during progression through the cell cycle, the viral mutants of the invention may be used for preferential, albeit not necessarily completely selective, killing of neoplastic cells, thus constituting a useful antineoplastic therapy modality to be used alone or in combination with other modalities of treatment. Deletions (or other inactivating mutations) in the 37 aminoterminal residues of the HPV E7 polypeptide are preferred HPV mutants for application to RB' cells, since these residues are important for RB binding.

Although the methods and compositions presented below are described specifically for methods relating to replication deficient adenoviral constructs, it is believed that the invention can be practiced with other DNA viruses encoding oncoproteins which sequester or enhance the degradation of p53 protein or RB protein, for example replication deficient papillomavirus species mutants of HPV types 16, 18, 33) that contain mutations in the E6 and/or E7 genes which substantially abrogate p53 and/or RB function, respectively.

In addition to members of the family Adenoviridae (specifically the genus Mastadenovirus), it is believed that members of the family Papovaviridae, especially papillomavirus and polyomavirus, which encode viral proteins that sequester and/or inactivate p53 or RB are suitable for use in the methods of the invention.

For a general description of adenovirus and papovavirus biology, Virology, Second edition, eds. Fields BN and Knipe DM, Vol.2, pp. 1651-1740, Raven Press, New York, NY, incorporated herein-by reference, may be referred to for guidance. The following specific descriptions refer to, but are not limited to, adenovirus serotype 5 and adenovirus serotype 2.

Although it is believed that other adenoviral serotypes may be used, adenovirus type 5 provides a common reference point for the nucleotide numbering convention of viral polynucleotides and amino acid numbering of viral-encoded polypeptides of the Ela viral gene region, and other viral genes. Adenovirus type 2 provides a convenient reference for the numbering convention of the Elb viral gene region, and other viral gene regions. It is believed that those of skill in the art will readily identify the corresponding positions in other adenoviral serotypes.

References to human papillomavirus generally refer to a type associated with neoplasia types 16, 18, or 33), although non-oncogenic types may also be used.

11 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 Elb Mutants A function of the cellular phosphoprotein p53 is to inhibit the progression of mammalian cells through the cell cycle. Wild-type adenovirus Elb p55 protein binds top53 in infected cells that have p53 and produce a substantial inactivation of p5 3 function, likely by sequestering p53 in an inactive form. Functional Elb p55 protein is essential for efficient adenoviral replication in cells containing functional p5 3 Hence, adenovirus variants which substantially lack the ability to bind p53 are replication deficient in non-replicating, nonneoplastic cells having normal levels of functional p53.

Human tumor cells frequently are homozygous or heterozygous for mutated substitution, deletion, frameshift mutants) p5 3 alleles, and lack p53 function necessary for normal control of the cell cycle (Hollstein et al. (1991) Science 253: 49; Levine et al.

(1991) op.cit., incorporated herein by reference). Thus, many neoplastic cells are p53 either because they lack sufficient levels of p53 protein and/or because they express mutant forms of p53 which are incapable of substantial p53 function, and which may substantially diminish p53 function even when wild-type p53 may be present by inhibiting formation of functional multimers). Some neoplastic cells may comprise alleles encoding essentially wild-type p53 proteins, but may comprise a second site mutation that substantially abrogates p53 function, such as a mutation that results in p53 protein being localized in the cytoplasm rather than in the nucleus; such second site mutants also substantially lack p5 3 function.

It is believed that replication deficient adenovirus species which lack the capacity to complex p5 3 but substantially retain other essential viral replicative functions will exhibit a replication phenotype in cells which are deficient in p53 function cells which are homozygous for substantially deleted p5 3 alleles, cells which comprise mutant p 5 3 proteins which are essentially nonfunctional) but will not substantially exhibit a replicative phenotype in non-replicating, non-neoplastic cells. Such replication deficient adenovirus species are referred to herein for convenience as Elb-p53" replication deficient adenoviruses.

A cell population (such as a mixed cell culture or a human cancer patient) which comprises a subpopulation of neoplastic cells lacking p53 function and a subpopulation of non-neoplastic cells which express essentially normal p5 3 function can be contacted under infective conditions conditions suitable for adenoviral infection of the cell population, typically physiological conditions) with a composition comprising an infectious dosage of a Elb-p53"' replication deficient adenovirus. Such contacting results in infection of the cell population with the Elb-p53'" replication deficient adenovirus. The infection produces 12 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 preferential expression of a replication phenotype in a significant fraction of the cells comprising the subpopulation of neoplastic cells lacking p53 function but does not produce a substantial expression of a replicative phenotype in the subpopulation of non-neoplastic cells having essentially normal p53 function. The expression of a replication phenotype in an infected p53" cell results in the death of the cell, such as bycytopathic effect (CPE), cell lysis, apoptosis, and the like, resulting in a selective ablation of neoplastic p53" cells from the cell population.

Typically, Elb-p53'" replication deficient adenovirus constructs suitable for selective killing of p53(-) neoplastic cells comprise mutations deletions, substitutions, frameshifts) which inactivate the ability of the Elb p55 polypeptide to bind p53 protein effectively. Such inactivating mutations typically occur in the regions of p55 which bindp53.

Optionally, the mutant Elb region may encode and express a functional p19 protein encoded by the Elb region remains and that is functional in transactivation of adenoviral early genes in the absence of El a polypeptides.

Suitable Elb-p53"' replication deficient adenovirus constructs for use in the methods and compositions of the invention include, but are not limited to the following examples: adenovirus type 2 dl 1520, which contains a C to T mutation at nucleotide position 2022 that generates a stop codon 3 amino acids downstream of the AUG codon used for initiation of translation of the p55 protein and a deletion between nucleotides 2496 and 3323 replaced with a small linker insertion that generates a second stop codon at nucleotide 3336; the expression of the p19 protein is essentially unaffected (Barker and Berk (1987) Virology 156: 107, incorporated herein by reference, and a composite adenovirus construct comprising adenovirus type 2 dl 1520 comprising at least the position 2022 mutation and/or the 2496-3323 deletion mutation, or a substantial portion thereof, and an additional mutation in p19 to yield a p19 cyt mutant; the composite virus construct lacks p55 and comprises the enhanced cytopathic effect of the p19 cyt mutation. Ad2 dl 1520 are available from Dr. A.

Berk, University of California at Los Angeles, Los Angeles, CA, and are described in the literature, including Barker and Berk (1987) Virology 156: 107, incorporated herein by reference.

It may be preferable to incorporate additional mutations into such adenovirus constructs to inhibit formation of infectious virions in neoplastic cells which otherwise would support replication of the Elb-p53" mutants. Such additional inactivating mutations would be preferred in therapeutic modalities wherein complete viral replication forming infectious 13 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 virions capable of spreading to and infecting adjacent cells is undesirable. These fully inactivated mutants are referred to as nonreplicable Elb-p53'" mutants. Such nonreplicable mutants comprise mutations which prevent formation of infectious virions even in p53-'RB cells; such mutations typically are structural mutations in an essential virion protein or protease.

However, in many modalities it is desirable for the mutant virus to be replicable and to form infectious virions containing the mutant viral genome which may spread and infect other cells, thus amplifying the antineoplastic action of an initial dosage of mutant virus.

Additional Elb"' mutants lacking the capacity to bind p53 can be generated by those of skill in the art by generating mutations in the Elb gene region encoding the polypeptide, expressing mutant p55 polypeptides, contacting the mutant p55 polypeptides with p53 or a binding fragment of p53 under aqueous binding conditions, and identifying mutant Elb polypeptides which do not specifically bind p 5 3 as being candidate Elb"' mutants suitable for use in the invention.

More typically, a functional assay will be used to identify candidate Elb'' mutants. For example, the Friend assay for determination of p53 function will be performed essentially as described in Frebourg et al. (1992) Cancer Res. 52: 6977, incorporated herein by reference. Elb mutants which lack the capacity to inactivate p53 will be identified as candidate Elb'' replication deficient mutants.

Ela/Elb Double Mutants Some human tumor cells lack both p53 function and RB function, either by mutational inactivation or deletion of one or both protein species. Such cells are termed p53 cells.

It is believed that replication deficient adenovirus species which lack the capacity to bind p53 and which also lack the capacity to bind RB, but which substantially retain other essential viral replicative functions will preferentially exhibit a replication phenotype in p53' t RB'' cells. Such replication deficient adenovirus species are referred to herein for convenience as Ela-RB'-/Elb-p53 replication deficient adenoviruses, or simply Ela/Elb double mutants. Such Ela/Elb double mutants can be constructed by those of skill in the art by combining at least one Ela-RB'' mutation in the Ela region and at least one Elb-p53'' mutation in Elb region encoding p55 to form a Ela/Elb double mutant adenovirus. Such a replication deficient double mutant adenovirus will exhibit a replication phenotype in cells which are deficient in both p53 and RB functions but will not substantially exhibit a replicative 14 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 phenotype in non-replicating, non-transformed cells or in cells which are deficient in eitherp53 or RB function but not both functions. For example, the Ad5 dl 434 mutant (Grodzicker et al.

(1980) Cell 21: 454, incorporated herein by reference) comprises a deletion of the Ela locus and a partial deletion of the Elb locus, and substantially lacks the capacity to encode functional Ela and Elb p55 proteins.

A cell population (such as a mixed cell culture or a human cancer patient) which comprises a subpopulation of neoplastic cells lacking p53 and RB functions and a subpopulation of non-neoplastic cells which express essentially normalp53 function and/or RB function can be contacted under infective conditions conditions suitable for adenoviral infection of the cell population, typically physiological conditions) with a composition comprising an infectious dosage of a replication deficient Ela/Elb double mutant adenovirus.

Such contacting results in infection of the cell population with the Ela/Elb double mutant replication deficient adenovirus. The infection produces preferential expression of a replication phenotype in a significant fraction of the cells comprising the subpopulation of neoplastic cells lacking both p53 function and RB function but does not produce a substantial expression of a replicative phenotype in the subpopulation of non-neoplastic cells having essentially normal p53 function and/or RB function. The expression of a replication phenotype in an infected p53 'RB" cell results in the death of the cell, such as by cytopathic effect (CPE), cell lysis, and the like, resulting in a selective ablation of neoplastic p53'-RB'' cells from the cell population.

It may be preferable to incorporate additional mutations into such adenovirus constructs to inhibit formation of infectious virions in neoplastic cells which otherwise would support replication of an Ela/Elb double mutant. Such additional inactivating mutations would be preferred in therapeutic modalities wherein complete viral replication forming infectious virions capable of spreading to and infecting adjacent cells is undesirable. These fully inactivated mutants are referred to as nonreplicable Ela/ Elb double mutants. Such nonreplicable mutants comprise mutations which prevent formation of infectious virions even in p53''RB" cells; such mutations typically are structural mutations in an essential virion protein or protease.

However, in many modalities it is desirable for the mutant virus to be replicable and to form infectious virions containing the mutant viral genome which may spread and infect other cells, thus amplifying the antineoplastic action of an initial dosage of mutant virus.

SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 Negative Selection Viral Constructs Although expression of an adenoviral replication phenotype in an infected cell correlates with viral-induced cytotoxicity, generally by cell lysis, cytopathic effect (CPE), apoptosis, or other mechanisms of cell death, it may often be preferable to augment the cytotoxicity of a recombinant adenovirus that is to be used for antineoplastic therapy. Such augmentation may take the form of including a negative selection gene in the recombinant adenovirus, typically operably linked to an adenoviral promoter which exhibits positive transcriptional modulation in cells expressing a replication phenotype. For example, a HSVtk gene cassette may be operably linked immediately downstream of an E3 promoter of a replication deficient adenovirus, such as Ad5 NT dl 1110. Frequently, it is desirable to delete a nonessential portion for viral replication and packaging) of the adenoviral genome to accommodate the negative selection cassette; thus a substantial portion of the E3 gene region may be deleted and replaced with a negative selection cassette such as an HSV tk gene operably linked to an E2 promoter (and enhancer) or other suitable promoter/enhancer.

Alternatively, a negative selection gene may be operably linked to an adenovirus late region promoter to afford efficient expression of the negative selection gene product in cells expressing a replication phenotype characterized by transcription from late gene promoters.

For embodiments where viral replication forming infectious virions in vivo is undesirable, adenovirus replication deficient constructs which arenonreplicable are used. Such nonreplicable mutants comprise an Ela'' and/or Elb'" mutation and comprise all genetic functions necessary for generating a replication phenotype in a suitable neoplastic cell a p53"' cell, a RB" cell, or a p53"'RB"' cell) but have deleted at least one essential gene function necessary for formation of infectious virions, such as structural coat proteins, proteases, and the like. Alternatively, an elicited immune response evoked by the virus may neutralize infectious virions and moderate spread of the viral infection. Nonreplicable mutants lacking a complementable trans-acting function in addition to an Ela and/or Elb mutation may be propagated in conjunction with a complementary helper virus or a helper cell line capable of providing the deleted trans-acting function(s). For example, the 293 cell line (ATCC CRL 1573; Graham et al. (1977) J. Gen. Virol. 36: 59, incorporated herein by reference) which provides Ela and Elb functions in trans may be modified to provide additional functions in trans, such as a virion coat protein or the like, to permit propagation of the "nonreplicable" mutants for developing virus stocks.

16 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 Expression of the HSV tk gene in a cell is not directly toxic to the cell, unless the cell is exposed to a negative selection agent such as gancyclovir or FIAU. Infected cells expressing a replication phenotype wherein a negative selection gene is substantially expressed may produce essentially no additional cytotoxicity until the negative selection agent gancyclovir) is administered in an effective selective dosage, at which time the infected cells expressing the tk gene will be selectively ablated; thus negative selection can be used for enhanced cytopathic killing and/or to damp out further viral replication by killing cells exhibiting a replicative phenotype. Further, by adjusting the dosages and/or administration schedule of the negative selection agent, it is possible to produce only a partial ablation of the infected cell population expressing the negative selection gene. Generally, the dosage of gancyclovir is calibrated by generating a standard dose-response curve and determining the dosage level at which a desired level of ablation of infected neoplastic cells is observed.

Information regarding administration of gancyclovir (GANC) to animals is available in various sources in the art, including human prescribing directions from package inserts. When used in cell culture, a selective concentration of gancyclovir is typically in the range of 0.05mM to mM, typically about 1 mM, with about 0.2 mM used for in vitro applications and about mM administered for in vivo applications (typically administered over about 24 hours by continuous infusion from an osmotic pump loaded with 125mg/ml of gancyclovir in aqueous solution). A dosage schedule for in vivo administration may comprise gancyclovir at a dosage of 5 mg/kg bodyweight given intravenously for seven days.

Negative selection genes may be incorporated into Ela-RB'" replication deficient adenovirus constructs, Elba-p53" replication deficient adenoviral constructs, Ela/Elb double mutant replication deficient viral constructs, or the like. A preferred embodiment is an HSV tk gene cassette (Zjilstra et al. (1989) Nature 342:435; Mansour et al. (1988) Nature 336: 348; Johnson et al. (1989) Science 245: 1234: Adair et al. (1989) Proc. Natl. Acad. Sci 86: 4574; Capecchi, M. (1989) Science 244:1288, incorporated herein by reference) operably linked to the E2 promoter of Ad5 NT dil 10 or an alternative promoter and/or enhancer major late promoter, Ela promoter/enhancer, Elb promoter/enhancer), with a polydenylation site to form a tk expression cassette. The tk expression cassette (or other negative selection expression cassette) is inserted into the adenoviral genome, for example, as a replacement for a substantial deletion of the E3 gene. Other negative selection genes and replication deficient adenovirus constructs will be apparent to those of skill in the art. It is believed that a negative selection gene operably linked to the E2 promoter is an especially 17 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 preferred embodiment for incorporation into Ela' replication-deficient adenovirus mutants, as the E2 promoter contains multiple E2F sites, whereas RB and p53'*RB'? lack RB function and presumably will exhibit more efficient transcription from the E2 promoter.

Diagnostic and In Vitro Uses The replication deficient adenoviruses of the invention may be used to detect the presence of cells lacking p53 and/or RB function. For example, a cell sample comprising a subpopulation of neoplastic cells lacking p53 and/or RB can be infected with a suitable replication deficient adenovirus species. After a suitable incubation period, the cells in the cell sample that express a replication phenotype loss of ability to exclude Trypan blue, virion formation, 'H-thymidine incorporation into viral DNA) can be quantified to provide a measure of the number or proportion of replicative and/or neoplastic cells in the cell sample. Such methods may be used to diagnose neoplasms and/or evaluate tumor cell load following chemotherapy in a patient on the basis of an explanted cell sample a lymphocyte sample from a patient undergoing chemotherapy for a lymphocytic leukemia).

Alternative diagnostic uses and variations are apparent; for example, a reporter gene luciferase, b-galactosidase) may be substituted for a negative selection gene in a replication deficient adenovirus; transformed cells may be scored (such as in a cellular sample or transformation assay) by the expression of the reporter gene, which is correlated with expression of a replication phenotype indicating a lack of p53 and/or RB in a cell.

Therapeutic Methods Therapy of neoplastic disease may be afforded by administering to a patient a composition comprising replication defective adenoviruses of the invention, including: Ela- RB"' replication deficient adenoviruses, Elb-p53''' replication deficient adenoviruses, Ela/Elb double mutants, and replication deficient adenoviruses further comprising a negative selection gene.

Various human neoplasms comprising cells that lack p5 3 and/or RB functions may be treated with the replication deficient adenoviral constructs. For example but not limitation, a human patient or nonhuman mammal having a bronchogenic carcinoma, nasopharyngeal carcinoma, laryngeal carcinoma, small cell and non-small cell lung carcinoma, lung adenocarcinoma, hepatocarcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, breast carcinoma, cervical carcinoma, ovarian carcinoma, orlymphocytic leukemias may be treated by administering an effective antineoplastic dosage of an appropriate replication deficient adenovirus. Suspensions of infectious adenovirus particles may be applied to 18 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 neoplastic tissue by various routes, including intravenous, intraperitoneal, intramuscular, subdermal, and topical. A adenovirus suspension containing about 10' to 102 or more virion particles per ml may be inhaled as a mist for pulmonary delivery to treat bronchogenic carcinoma, small-cell lung carcinoma, non-small cell lung carcinoma, lung adenocarcinoma, or laryngeal cancer) or swabbed directly on a tumor site for treating a tumor bronchogenic carcinoma, nasopharyngeal carcinoma, laryngeal carcinoma, cervical carcinoma) or may be administered by infusion into the peritoneal cavity for treating ovarian cancer, into the portal vein for treating hepatocarcinoma or liver metastases from other non-hepatic primary tumors) or other suitable route, including direct injection into a tumor mass a breast tumor), enema colon cancer), or catheter bladder cancer).

Candidate antineoplastic adenovirus mutants may be further evaluated by their capacity to reduce tumorigenesis or neoplastic cell burden in nu/nu mice harboring a transplant of neoplastic cells lacking p 5 3 and/or RB function, as compared to untreated mice harboring an equivalent transplant of the neoplastic cells.

Antineoplastic replication deficient adenovirus mutants may be formulated for therapeutic and diagnostic administration to a patient having a neoplastic disease.

For therapeutic or prophylactic uses, a sterile composition containing a pharmacologically effective dosage of one or more species of antineoplastic replication deficient adenovirus mutant is administered to a human patient or veterinary non-human patient for treatment of a neoplastic condition. Generally, the composition will comprise about to 10" or more adenovirus particles in an aqueous suspension. A pharmaceutically acceptable carrier or excipient is often employed in such sterile compositions. A variety of aqueous solutions can be used, water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter other than the desired adenoviral virions. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. Excipients which enhance infection of cells by adenovirus may be included.

Replication deficient viruses may be delivered to neoplastic cells by liposome or immunoliposome delivery; such delivery may be selectively targeted to neoplastic cells on the basis of a cell surface property present on the neoplastic cell population the presence of a cell surface protein which binds an immunoglobulin in an immunoliposome). Typically, an 19 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 aqueous suspension containing the virions are encapsulated in liposomes or immunoliposomes.

For example, a suspension of replication deficient adenovirus virions can be encapsulated in micelles to form immunoliposomes by conventional methods Patent 5,043,164, U.S.

Patent 4,957,735, U.S. Patent 4,925,661; Connor and Huang (1985) J. Cell Biol. 101: 582; Lasic DD (1992) Nature 355: 279; Novel Drug Delivery (eds. Prescott LF and Nimmo WS: Wiley, New York, 1989); Reddy et al. (1992) J. Immunol. 148: 1585; incorporated herein by reference). Immunoliposomes comprising an antibody that binds specifically to a cancer cell antigen CALLA, CEA) present on the cancer cells of the individual may be used to target virions to those cells.

The compositions containing the present antineoplastic replication deficient adenoviruses or cocktails thereof can be administered for prophylactic and/or therapeutic treatments of neoplastic disease. In therapeutic application, compositions are administered to a patient already affected by the particular neoplastic disease, in an amount sufficient to cure or at least partially arrest the condition and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose" or "efficacious dose." Amounts effective for this use will depend upon the severity of the condition, the general state of the patient, and the route of administration.

In prophylactic applications, compositions containing the antineoplastic replication deficient adenoviruses or cocktails thereof are administered to a patient not presently in a neoplastic disease state to enhance the patient's resistance to recurrence of a neoplasm or to prolong remission time. Such an amount is defined to be a "prophylactically effective dose." In this use, the precise amounts again depend upon the patient's state of health and general level of immunity.

Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the antineoplastic replication deficient adenoviruses of this invention sufficient to effectively treat the patient.

Antineoplastic replication deficient adenoviral therapy of the present invention may be combined with other antineoplastic protocols, such as conventional chemotherapy and/or immunosuppression. The procedures for immunosuppression would consist of those essentially described in WO 96/12406. Generally, a replication deficient adenovirus would be administered alone or in admixture with an immunosuppressive agent. Examples of preferred immunosuppressive compounds include cyclophosphamide, cyclosporine, or dexamethasone.

SUBSTITUTE SHEET rule 26) WO 98/29555 PCT/US97/22036 The dosages of these compounds to realize a desired level ofimmunosuppression are known in the art. For example, cyclophosphamide is preferrably administered at between 100-300mg/kg, while dexamethasone is preferrably administered at about 2-6 mg/kg.

Propagation of Mutant Adenovirus Adenoviral mutants of the invention Ela-RB" replication deficient adenoviruses, Elb-p53" replication deficient adenoviruses, and Ela/Elb double mutants) typically are propagated as viral stocks in a cell line the 293 cell line ATCC CRL 1573, American Type Culture Collection, Rockville, MD; Graham et al. (1977) J. Gen. Virol. 36: 59) which can provide Ela function, Elb function, or both Ela and Elb functions, respectively, in trans to support replication and formation of infectious mutant virions.

The following examples are offered by way of example and not by way of limitation. Variations and alternate embodiments will be apparent to those of skill in the art.

EXPERIMENTAL EXAMPLES Effect of Replication-Deficient Recombinant Adenovirus on Neoplastic Cells lacking p53 and /or Rb The following experimental example demonstrates that administering a replication-deficient recombinant adenovirus preparation to neoplastic cells lackingp53 and/or Rb function can effectively kill neoplastic cells. The example also shows that non-neoplastic cells containing p53 and Rb function are relatively resistant to killing by the replicationdeficient recombinant adenovirus preparation. Therefore, the data presented hereinbelow provide experimental verification that administration of replication-deficient recombinant adenovirus can be used to selectively kill neoplastic cells. The selective killing is provided by exploiting the differential ability of the mutant adenoviruses to induce a replication phenotype in neoplastic cells, but substantially not induce a replication phenotype (or associated cytopathic effect) in non-neoplastic cells.

Control non-neoplastic cells and cell lines representing a variety of neoplastic cell types were plated in 6-well culture dishes at or near confluence in DMEM (high glucose) with 10% fetal bovine serum and incubated at 37 0 C, 5% CO, under standard culturing conditions. Cells were plated to be screened at a density of 5 x 10' cells/well. The neoplastic cell lines tested were: SAOS-2 (ATCC HTB85), derived from a human primary osteogenic sarcoma; U-20S (ATCC HTB96), derived from a human osteogenic sarcoma; HS700T, (ATCC HTB147), derived from a human metastatic adenocarcinoma originating in the pancreas or intestines; 293 (ATCC CRL1573), transformed human embryonal kidney; and 21 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 DLD-1 (ATCC CCL221), derived from a human colon adenocarcinoma. Each of the cell lines is available from American Type Culture Collection, Rockville, MD. The control nonneoplastic cells were IMR90 (ATCC CCL 186) and WI-38 (ATCC CCL 75), both diploid human lung fibroblast lines.

These cell cultures were subsequently infected, in parallel, with wild-type adenovirus Type 2, and replication-deficient recombinant adenovirus mutants dl 1010, dl 434, and dl 1520. An extra culture dish was plated for the purpose of counting cells. These cells came from the same suspension of cells used for the viral infections. Cells were counted in order to determine the number of viral plaque-forming units (PFU) to add to the cell cultures for a desired multiplicity of infection (MOI). The wild-type adenovirus Type 2 and the mutant adenoviruses were added to the parallel cell cultures at MOIs of 0.1, 1.0, 10, and 100. Virus suspended in PBS was added to the cell wells in a volume of 1 ml. The inoculated culture dishes were rocked in both the X- and Y- axes immediately after inoculation and halfway through the adsorption time of approximately one hour at 37 0 C, 5% CO,. After the one hour adsorption period, 2 ml of DMEM with high glucose and 2% fetal bovine serum was added, and the cultures incubated at 37 0 C, 5% CO, under standard culturing conditions. At various times after infection cell cultures were stained with 0.5% crystal violet in 20% methanol in order to determine the efficacy of cell killing by the virus preparations. Dead cells were detached and rinsed out of the wells, whereas living cells remained in the well and were stained with the dye. The results demonstrate that the replication-deficient recombinant adenovirus preparations were able to preferentially kill neoplastic cells as compared to non-neoplastic cells, and that wild-type adenovirus Type 2 killed both neoplastic and non-neoplastic cells approximately equally well. More particularly, the results demonstrated that the dl 1010 mutant was particularly effective at killing neoplastic cells, with the dl 1520 mutant and the dl 434 mutant also being effective. Wild-type adenovirus 2, over days 4-7 post-infection, was able to kill cells in each of the culture wells, although with variable efficacy and incompletely, with at least some cells staining in each well. Note that WI-38 and SAOS-2 lines are not good hosts for adenovirus infection and, as discussed below, IMR90, serves as an alternate control cell line for human diploid fibroblasts. The dl 1010 mutant, over days 8-12 was able to kill effectively all of the neoplastic cell lines except the infection-resistant SAOS-2. DI 1010 killed the 293, HS700T, and DLD-1 lines by 12 days after infection and did not substantially kill diploid human lung fibroblasts (WI-38). The dl 1520 mutant was able to kill effectively 3 of the 5 neoplastic cell lines (293, HS700T, and DLD-1) by 14-20 days after infection and did not 22 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 substantially kill diploid human lung fibroblasts (WI-38). dl 1520 is an E1B" mutant, and cell line U20S does not allow such an ElB" mutant virus to replicate, indicating specificity of the different transformed cell lines for infection by the mutant recombination-defective adenoviruses, as predicted. The dl 434 mutant (a double-mutant: EIA"E1B") was able to kill effectively 3 of the 5 neoplastic cell lines (293, HS700T, and DLD-1) by 14-20 days after infection and did not substantially kill diploid human lung fibroblasts (WI-38). The DLD-1 and U20S lines displayed a partially resistant phenotype for replication of dl 434. Each cell line was mock infected with PBS alone as a control for viability.

The following experiments were also conducted using IMR90 cells (ATCC CCL 186) and wild-type and mutant adenoviruses. IMR90 cells were infected with the indicated virus at MOIs corresponding to 0.1, 1.0, 10, and 100. At nine days post-infection, cells were washed with PBS and stained with crystal violet. One well in each 6-well dish was seeded with 293 cells to serve as a positive control for virus infection. The results showed that human diploid lung fibroblasts were killed differentially by wild-type Ad2, dl 1010, and dl 1520. Wild-type Ad2 killed the IMR90 cells effectively at an MOI of 10 or 100. DI 1010 was unable to replicate in IMR90 cells at the highest MOI tested, even though dl 1010 killed neoplastic cell lines 293, U20S, HS700T, and DLD-1 as shown above. DI 1520 virus was able to kill IMR90 cells effectively only at an MOI of 100; at this high dosage of virus the possibility that the cells die as a result of virus overload rather than replication cannot be ruled out.

Thus, the data show that replication-deficient recombinant adenovirus mutants can be used to selectively kill neoplastic cells lacking p 5 3 and/or Rb function, as predicted.

Construction of Replication-Deficient Recombinant Adenovirus The following paragraphs describe the generation and testing of ONYX-019, ONYX-020, and ONYX-021, improved adenovirus strains with deletions in E1B 55kD which selectively replicate in p53-deficient cells. These strains have been compared to d11520 (hereinafter termed ONYX-015) and show significant improvement over ONYX-015 in viral CPE assays.

The practice of this aspect of the invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA manipulation and production, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, Sambrook, Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II N. Glover, 23 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 Ed. 1985); Oligonucleotide Synthesis J. Gait, Ed. 1984); Nucleic Acid Hybridization

D.

Hames and S. J. Higgins, Eds. 1984); Transcription and Translation D. Hames and S. J.

Higgins, Eds. 1984); Animal Cell Culture I. Freshney, Ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the series, Methods in Enzymology (Academic Press, Inc.); Gene Transfer Vectors for Mammalian Cells H. Miller and M. P. Calos, Eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology, Volumes 154 and 155 (Wu and Grossman, and Wu, Eds., respectively), (Mayer and Walker, Eds.) (1987); Immunochemical Methods in Cell and Molecular Biology (Academic Press, London), Scopes, (1987); Protein Purification: Principles and Practice, Second Edition (Springer-Verlag, and Handbook of Experimental Immunology, Volumes I-IV M. Weir and C. C. Blackwell, Eds 1986). All patents, patent applications and publications mentioned herein, both supra and infra, are hereby incorporated by reference.

DNA constructs: Nucleotides 1339-3328 were cut out of the Ad5 pXC1 plasmid obtained from Microbix Biosystems, Inc., Toronto, Ontario, Canada, using Xbal and Bgl2 restriction enzymes. pXC1 contains Ad5 sequences from base pair 22 to 5790. Nucleotides 1339-3328 encompass most of the E1B 55kD gene; it does not include the last C-terminal 178 base pairs. The gel purified DNA fragment was cloned into a modified Bluscript (Stratagene Corporation) vector (pBS Bgl AHin); which replaced the HindIII site with a Bgl2.

Oligonucleotides were made to both ends of the 1339-3328 fragment as well as internally (see Figure The oligos are as follows: 5'-CCGCTCTAGAGAATGCAATAGTAGTAC-3' Ad5: 1339-1361nt 5'-CTCCAGATCTTCATGGTCATGTC-3' Ad5: 3315-3328nt E1B217B= 5'-GGGGAATITCAAAGGCCACCCTATCCTCCGTATC-3' Ad5: 2646-2669nt EIB275T= 5'-GGGAATICACCGATGTAAGGGTTCGGGGCTGTG-3' Ad5: 2844-2868nt ElB300T= 5'-GGGAATrCTCAATTAAGAAATGCCTCITGAAAG-3' Ad5: 2919-2944nt E B354T= 5'-GGGAATTCGCCTCTCAGATGCTGACCTGCTCG-3' Ad5: 3081-3104nt 24 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 These oligos were used for PCR to generate different fragments designated A,B,C and D. The fragments were gel purified.

The following pairs of fragments: A and B, A and C, A and D were each ligated into the gel purified Bgl2/Xbal 7.9 Kb fragment of pXC1. After transformation into alpha cells colonies were screened via PCR using oligos: A5XBAT and A5BGLB to look for positives. See, U.S. Patent No. 5,008,182 and Hedrum, PCR Methods and Applications 2:167- 71(1992).

These constructs contain DNA sequences which encode deletions of the following amino acids in the E1B 55kD gene: p019 (pXCl-AB) made from fragments A and B deletion of AA 218-275 p020 (pXC 1-AC) made from fragments A and C deletion of AA 218-300 p021 (pXC 1-AD) made from fragments A and D deletion of AA 218-354 Figure 2 shows the above described fragments.

DNA maxi preps (Qiagen) were done on one positive of each construct. The DNA was sequenced to confirm deletions. The plasmids p019, p020 and p021 are in Escherichia coli and are on deposit with the American Type Culture Collection, and there are referred to as JN 019, JN 020, and JN 021, respectively. The American Type Culture Collection Accession Numbers are ATCC No. 98286 for JN 019; ATCC No. 98287 for JN 020; and ATCC No. for 98288 JN 021.

Virus constructs: HEK293 cells were co-transfected with the pBHGE3 plasmid obtained from Microbix, and with each of the plasmids p019, p020 and p021. The pBHGE3 plasmid contains a deletion of Ad5 El sequences from base pairs 188 to 1339 and is used to construct Ad5 vectors with insertions or mutations in the early region 1. Plaques were picked and PCR analysis was done on the first plugs using oligos A5XBAT and A5BGLB to confirm the presence of the partially deleted E1B 55kD gene. PCR methods are well known in the art that show the use of probes in nucleic acid hybridization assays to amplify target genetic material. See for example, U.S. Patent Nos. 4,683,202; 4,683,195; 5,091,310; 5,008,182 and 5,168,039. Plaques were expanded and viral DNA was made using the Qiagen QIAamp Blood.

The DNA was sequenced upstream and downstream of the deletions to confirm the deletions.

SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036 Immunoprecipitation data: Immunoprecipitation data using virus from lysed C33A cells showed that the viruses ONYX-019, ONYX-020 and ONYX-021 (corresponding to p019, p020 and p021 above) appear to make slightly more 19kD protein than ONYX-015 using anti-19kD antibody from Oncogene Sciences; make a version of the 55kD protein which is of lower molecular weight than wild-type 55kD using an anti-55kD antibody from Oncogene Sciences; note that ONYX-015 does not make detectable 55kD; and reacts as expected with antibody to adenovirus using an anti-adenovirus antibody from abV Immune Response.

CPE data: Data from CPE assays using C33A comparing ONYX-015 to ONYX-019, ONYX-020 and ONYX-021 showed that the new strains were approximately 2 to 10 fold more potent than ONYX-015 as measured by MOI required to produce an equivalent CPE effect.

These experiments were performed as described above. Briefly, the wild-type adenovirus Type 2 and the mutant adenoviruses, ONYX-015 to ONYX-019, ONYX-020 and ONYX-021, were added to the parallel cell cultures at MOIs of 0.1, 1.0, 10, and 100. Virus suspended in PBS was added to the cell wells in a volume of 1 ml. The inoculated culture dishes were rocked in both the X- and Y- axes immediately after inoculation and halfway through the adsorption time of approximately one hour at 37 0 C, 5% CO,. After the one hour adsorption period, 2 ml of DMEM with high glucose and 2% fetal bovine serum was added, and the cultures incubated at 37°C, 5% CO, under standard culturing conditions. Seven days post infection cell cultures were stained with 0.5% crystal violet in 20% methanol in order to determine the efficacy of cell killing by the virus preparations. Dead cells were detached and rinsed out of the wells, whereas living cells remained in the well and were stained with the dye.

The results demonstrated that the replication-deficient recombinant adenovirus preparations ONYX 015, ONYX-019, ONYX-020 and ONYX-021 were able to preferentially kill neoplastic cells as compared to non-neoplastic cells, and that wild-type adenovirus Type 2 killed both neoplastic and non-neoplastic cells approximately equally well.

The results further demonstrated that ONYX-019, ONYX-020 and ONYX-021 were 2fold more potent at killing C33A cells than ONYX-015 as measured by a MOI required to produce an equivalent CPE effect. The experiment was conducted over a MOI range of 10, 0.1, and 0.01, and ONYX-019, ONYX-020 and ONYX-021 exhibited the enhanced killing at at MOI of 0.1-0.01.

26 SUBSTITUTE SHEET rule 26) WO 98/29555 PCT/US97/22036 Effect of Replication-Deficient Recombinant Adenovirus and Chemotherapy on Tumor Cell Killing We next studied the efficacy of ONYX-015 (d11520) given intravenously (IV) alone, and in combination with chemotherapy. Human tumor xenografts (colon, cervical) were grown subcutaneously in nude mice to a size of 5-7 mm at which time 10 total pfu were injected IV in divided doses (days Mice in the chemotherapy groups received 5FU or cisplatinum at maximally-tolerated doses via intraperitoneal (IP) injection on day 5. Controls received IV and IP vehicle injections in identical fashion. Intratumoral virus replication was noted following IV administration. While cisplatinum and 5-FU did not significantly improve survival or inhibit tumor growth, ONYX-015 alone inhibited tumor growth significantly and improved survival 0.05). Combination therapy with ONYX-015 and either or cisplatinum led to significantly improved survival versus any agent alone. Thus, ONYX-015 has selective antitumoral activity when administered IV which can be improved with chemotherapy.

Although the present invention has been described in some detail by way of illustration for purposes of clarity of understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the claims.

27 SUBSTITUTE SHEET rule 26

Claims (28)

1. method for ablating neoplastic cells im a cell population, comprising the steps of: contacting under infective conditions a recombinant replication deficient adenovirus lacking an expressed viral oncoprotein capable of binding a functional tumor suppressor gene product said adenovirus having the properties of an adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021, with a cell population comprising non-neoplastic cells containing said functional tumor suppressor gene product capable of forming a bound complex with a viral oncoprotein and neoplastic cells lacking said functional tumor suppressor gene product, thereby generating an infected cell population.

2. A method according to claim I, wherein the viral oncoprotein is an adenovirus Elb polypeptide.

3. A method according to claim 1, wherein the tumor suppressor gene product is p5 3

4. A method according to claim 1, wherein the neoplastic cells are p53

5. A method according to claim 4, wherein the recombinant replication *deficient adenovirus does not encode a Elb p5 5 polypeptide capable of binding p 53

6. A method according to claim 1, wherein the recombinant replication I* deficient adenovirus is selected from the group consisting of Onyx 019, Onyx 020, or Onyx

021. 7. A method according to claim 1, wherein said cell population comprising neoplastic cells and non-neoplastic cells is present in a mammal and said contacting step is performed in vivo by administering the recombinant replication deficient adenovirus to an individual. 8. A method according to claim 7, wherein the mammal is a human. 9. A method according to claim 1, wherein the recombinant replication deficient adenovirus can be replicated to form infectious virions in a neoplastic cell lackingp53 function. A method according to claim 9, wherein the infectious virions formed in the neoplastic cell are able to spread and infect adjacent cells invivo in a patient. 11. A method according to claim 1, wherein the recombinant replication deficient adenovirus is nonreplicable for forming infectious virions in neoplastic cells of a human patient. WO 98/29555 PCT/US97/22036 12. A method according to claim 1, wherein the recombinant replication deficient adenovirus further includes a genetic alteration in Ela that prevents binding to the tumor suppressor Rb. 13. A method for treating a neoplastic condition in a human, comprising administering a composition comprising a therapeutically effective dosage of recombinant replication deficient adenovirus having the properties of an adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021 to a human patient having a neoplasm comprising neoplastic cells lacking a functional tumor suppressor gene product. 14. A method according to claim 13, wherein the tumor suppressor gene product is p53 A method according to claim 13, wherein the composition comprising a recombinant replication deficient adenovirus further includes a genetic alteration to the Ela region of said replication deficient adenovirus. 16. A method according to claim 15, wherein the genetic alteration to the El a region of said replication deficient adenovirus substantially prevents binding to a RB tumor suppressor gene product. 17. A method according to claim 16, wherein said neoplasm comprises neoplastic cells that lack either the tumor suppressor Rb, or the tumor suppressor p53, or both tumor suppressors. 18. A method according to claim 13 or 15, wherein the composition comprising a recombinant replication deficient adenovirus further comprises an operably linked negative selection gene. 19. A method according to claim 18 wherein the virus is selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021. 20. An antineoplastic composition for therapy of neoplastic disease, comprising a therapeutically effective dosage of a recombinant replication deficient adenovirus having the properties of an adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021 in a pharmaceutically deliverable form. 21. A recombinant plasmid, JN019, on deposit with the American Type Culture Collection with Accession number 98286.

22. A recombinant plasmid, JN020, on deposit with the American Type Culture Collection with Accession number 98287. 29 SUBSTITUTE SHEET rule 26 WO 98/29555 PCT/US97/22036

23. A recombinant plasmid, JN021, on deposit with the American Type Culture Collection with Accession number 98288.

24. A replication deficient adenovirus having the properties of an adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021.

25. A replication deficient adenovirus Onyx 019.

26. A replication deficient adenovirus Onyx 020.

27. A replication deficient adenovirus Onyx 021.

28. An isolated nucleic acid sequence present in a recombinant plasmid, JN019, said plasmid on deposit with the ATCC with accession number 98286, said nucleic sequence comprising a deletion in the ElB region of adenovirus, said deletion encoding amino acids 218-275.

29. An isolated nucleic acid sequence present in a recombinant plasmid, JN020, said plasmid on deposit with the ATCC with accession number 98287, said nucleic sequence comprising a deletion in the E1B region of adenovirus, said deletion encoding amino acids 218-300. An isolated nucleic acid sequence present in a recombinant plasmid, JN021, said plasmid on deposit with the ATCC with accession number 98288, said nucleic sequence comprising a deletion in the ElB region of adenovirus, said deletion encoding amino acids 218-354.

31. A method according to claim 1 or 12, further comprising contacting said neoplastic cells with an immunosuppressive or chemotherapeutic compound.

32. A composition comprising a recombinant replication deficient adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021, and a chemotherapeutic compound.

33. A composition comprising a recombinant replication deficient adenovirus having the properties of an adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021, and a chemotherapeutic compound.

34. A composition comprising a recombinant replication deficient adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021, and an immunosuppressive compound. A composition comprising a recombinant replication deficient adenovirus having the properties of an adenovirus selected from the group consisting of Onyx 019, Onyx 020, or Onyx 021, and an immunosuppressive compound. SUBSTITUTE SHEET rule 26 31

36. A host cell comprising a plasmid selected from the group consisting of JN019, JN020 and JN021.

37. A use of a composition comprising a therapeutically effective dosage of recombinant replication deficient adenovirus having the properties of an adenovirus selected from the group consisting of Onyx 019, Onyx 020 or Onyx 021 in the preparation of a medicament for treating a neoplastic condition in a human patient having a neoplasm comprising neoplastic cells lacking a functional tumor suppressor gene product.

38. A use according to claim 37, wherein the tumor suppressor gene product is p53.

39. A use according to any one of claims 37 or 38, wherein the composition comprising a recombinant deficient adenovirus further includes a genetic alteration to the Ela region of said replication deficient adenovirus.

40. A use according to claim 39, wherein the genetic alteration to the Ela region of said replication deficient adenovirus substantially prevents binding to a RB tumor suppressor gene.

41. A use according to claim 40, wherein said neoplasm comprises neoplastic cells that lack either the tumor suppressor Rb, or the tumor suppressor p53, or both tumor suppressors.

42. A use according to any one of claims 37 or 39, wherein the composition comprising a recombinant replication deficient adenovirus further comprises an 6 operably linked negative selection gene.

43. A method for ablating neoplastic cells in a cell population according to claim 1 substantially as hereinbefore described with reference to any one of the examples.

44. A method for treating a neoplastic condition in a human according to claim 13 substantially as hereinbefore described with reference to any one of the examples. DATED 27 March 2000 PHILLIPS ORMONDE FITZPATRICK Attorneys for: ONYX PHARMACEUTICALS INC. W:\ElisabethPJCORK\583068p.doc